The Ministry of Health and Social Protection reported that, to date, there are no reasons to consider a risk in the supply of inputs, raw materials or finished products, derived from the impact generated by the easing of the zero covid policy in China, and its potential effects on the drug supply chain.
(WHO alert: asks China to strengthen its response against covid).
After the analysis and follow-up meeting convened by the health portfolio through the Medicines and Technologies department, the main unions of the pharmaceutical industry and non-union laboratories had the opportunity to report the current state of supply, verify the difficulties that could be perceived by the situation in China and the eventual impacts in the short and medium term.
According to what was stated in this meeting by the industry, To date there are no reasons to consider a risk in the supply of inputs, raw materials or finished products.
(China promises fiscal expansion to boost economy.)
For the sector, recent experience provides lessons from the crisis derived from the covid-19 pandemic and installed capacities, such as the strengthening of risk preventive measures through the increase in safety inventories and the identification of practical logistical alternatives to replace some ingredients, so a risk of shortages is not foreseen.
The same way, The unions reported that, although there have been some delays due to year-end issues, No information on problems has been received from suppliers that reports setbacks that affect the supply of raw materials or finished products for a long time.
(China: the turn in the ‘zero covid’ policy that has the world nervous).
Thus, the Ministry of Health and Social Protection, working jointly with INVIMA and the actors in the supply chain, will continue to monitor the situation to guarantee the availability of medicines in the country.
BRIEFCASE
